DexCom (NASDAQ:DXCM) had its price objective lifted by research analysts at BMO Capital Markets to $74.00 in a note issued to investors on Tuesday. The firm presently has an “outperform” rating on the medical device company’s stock. BMO Capital Markets’ price target would suggest a potential upside of 26.47% from the stock’s current price.

Several other brokerages have also weighed in on DXCM. Canaccord Genuity reissued a “buy” rating and set a $90.00 price objective on shares of DexCom in a report on Tuesday, August 22nd. ValuEngine raised DexCom from a “sell” rating to a “hold” rating in a report on Friday, September 1st. BidaskClub raised DexCom from a “sell” rating to a “hold” rating in a report on Saturday, August 19th. Barclays began coverage on DexCom in a report on Friday, September 15th. They set an “equal weight” rating and a $76.00 price objective for the company. Finally, Robert W. Baird reaffirmed a “hold” rating and issued a $79.00 price target on shares of DexCom in a report on Sunday, September 10th. One investment analyst has rated the stock with a sell rating, eight have issued a hold rating, fourteen have assigned a buy rating and one has issued a strong buy rating to the stock. The stock currently has a consensus rating of “Buy” and a consensus price target of $71.36.

Shares of DexCom (DXCM) traded up $1.26 during midday trading on Tuesday, reaching $58.51. The company’s stock had a trading volume of 1,206,600 shares, compared to its average volume of 1,456,272. DexCom has a 1-year low of $42.62 and a 1-year high of $88.80. The company has a debt-to-equity ratio of 0.84, a current ratio of 5.86 and a quick ratio of 5.50.

In other news, EVP Steven Robert Pacelli sold 1,450 shares of the firm’s stock in a transaction dated Monday, September 25th. The stock was sold at an average price of $69.81, for a total transaction of $101,224.50. The sale was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, EVP Richard Doubleday sold 1,635 shares of the firm’s stock in a transaction dated Monday, October 23rd. The shares were sold at an average price of $44.82, for a total value of $73,280.70. Following the transaction, the executive vice president now directly owns 65,049 shares in the company, valued at $2,915,496.18. The disclosure for this sale can be found here. Insiders have sold 43,955 shares of company stock worth $2,583,643 in the last 90 days. Company insiders own 1.70% of the company’s stock.

A number of institutional investors have recently bought and sold shares of DXCM. Advisor Group Inc. boosted its position in DexCom by 104.9% during the 2nd quarter. Advisor Group Inc. now owns 1,635 shares of the medical device company’s stock valued at $119,000 after acquiring an additional 837 shares in the last quarter. Zions Bancorporation lifted its holdings in shares of DexCom by 36,222.2% during the third quarter. Zions Bancorporation now owns 3,269 shares of the medical device company’s stock valued at $160,000 after purchasing an additional 3,260 shares during the last quarter. IFP Advisors Inc lifted its holdings in shares of DexCom by 30.5% during the second quarter. IFP Advisors Inc now owns 2,431 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 568 shares during the last quarter. Toronto Dominion Bank lifted its holdings in shares of DexCom by 251.0% during the third quarter. Toronto Dominion Bank now owns 3,647 shares of the medical device company’s stock valued at $178,000 after purchasing an additional 2,608 shares during the last quarter. Finally, Janney Montgomery Scott LLC lifted its holdings in shares of DexCom by 9.2% during the second quarter. Janney Montgomery Scott LLC now owns 2,959 shares of the medical device company’s stock valued at $216,000 after purchasing an additional 250 shares during the last quarter.

ILLEGAL ACTIVITY NOTICE: “DexCom (DXCM) PT Raised to $74.00 at BMO Capital Markets” was originally reported by Daily Political and is the property of of Daily Political. If you are viewing this article on another website, it was copied illegally and republished in violation of U.S. & international trademark & copyright laws. The legal version of this article can be accessed at https://www.dailypolitical.com/2017/12/14/dexcom-dxcm-pt-raised-to-74-00-at-bmo-capital-markets.html.

About DexCom

Dexcom, Inc (Dexcom) is a medical device company. The Company is focused on the design, development and commercialization of continuous glucose monitoring (CGM) systems for ambulatory use by people with diabetes and for use by healthcare providers. The Company’s products consist of DexCom G4 PLATINUM and DexCom G5 Mobile.

Analyst Recommendations for DexCom (NASDAQ:DXCM)

Receive News & Ratings for DexCom Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for DexCom and related companies with MarketBeat.com's FREE daily email newsletter.